Perspective on hormone therapy 10 years after the WHI.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Maturitas

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.maturitas.2013.08.014PMID 24094493
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Committee Opinion No. 556: Postmenopausal Estrogen Therapy Route of Administration and Risk of Venous Thromboembolism

  2013cited by this paper
• HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT

  2013cited by this paper
• Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model

  2013cited by this paper
• Ospemifene: First Global Approval

  2013cited by this paper
• A standardized phytopreparation from an Indian medicinal plant (Dalbergia sissoo) has antiresorptive and bone-forming effects on a postmenopausal osteoporosis model of rat

  2012cited by this paper
• Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice

  2012cited by this paper
• The Tissue Selective Estrogen Complex: A Novel Approach to the Treatment of Menopausal Symptoms

  2012cited by this paper
• Hormone therapy in postmenopausal women and risk of endometrial hyperplasia.

  2012cited by this paper
• Stellate-ganglion block as a treatment for severe postmenopausal flushing

  2012cited by this paper
• Micronized progesterone and its impact on the endometrium and breast vs. progestogens

  2012cited by this paper
• A decade after the Women’s Health Initiative—the experts do agree

  2012cited by this paper
• Recent developments in the clinical use of the levonorgestrel‐releasing intrauterine system

  2011cited by this paper
• Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy

  2011cited by this paper
• EMAS position statement: Managing the menopause in the context of coronary heart disease.

  2011cited by this paper
• EMAS position statement: Managing menopausal women with a personal or family history of VTE.

  2011cited by this paper
• Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study

  2010cited by this paper
• Hormone therapy in postmenopausal women and risk of endometrial hyperplasia.

  2009cited by this paper
• Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: A debated clinical issue

  2009cited by this paper
• A randomized, controlled pilot study of acupuncture treatment for menopausal hot flashes

  2008cited by this paper
• Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis

  2008cited by this paper
• The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women:2007 position statement of The North American Menopause Society

  2008cited by this paper
• The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society

  2007cited by this paper
• BMC Women's Health BioMed Central Research article Differences in Menopausal Hormone Therapy Use among Women

  2007cited by this paper
• Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

  2007cited by this paper
• Progesterone: review of safety for clinical studies.

  2007cited by this paper
• Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study.

  2006cited by this paper
• Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.

  2006cited by this paper
• Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration

  2005cited by this paper
• Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.

  2005cited by this paper
• Menopausal Symptoms and Treatment-Related Effects of Estrogen and Progestin in the Women's Health Initiative

  2005cited by this paper
• National Institutes of Health State-of-the-Science Conference Statement: Management of Menopause-Related Symptoms

  2005cited by this paper
• Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

  2004cited by this paper
• Changes in the Use of Postmenopausal Hormone Therapy after the Publication of Clinical Trial Results

  2004cited by this paper
• Phytoestrogens for Treatment of Menopausal Symptoms: A Systematic Review

  2004cited by this paper
• Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.

  2004cited by this paper
• Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative.

  2004cited by this paper
• Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes.

  2004cited by this paper
• A Three-Part Intervention To Change the Use of Hormone Replacement Therapy in Response to New Evidence

  2004cited by this paper
• National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

  2004cited by this paper
• Smoking, Body Mass, and Hot Flashes in Midlife Women

  2003cited by this paper
• Gabapentin's Effects on Hot Flashes in Postmenopausal Women: A Randomized Controlled Trial

  2003cited by this paper
• Bleeding Patterns of the Hormone Replacement Therapies in the Postmenopausal Estrogen and Progestin Interventions Trial

  2002cited by this paper
• Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Recommendations and Rationale

  2002cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.

  2001cited by this paper
• Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.

  2000cited by this paper
• Use of Hormone Replacement Therapy by Postmenopausal Women in the United States

  1999cited by this paper
• Vasomotor flushes in menopausal women.

  1999cited by this paper
• Hormone replacement therapy, heart disease, and other considerations.

  1998cited by this paper
• COMBINED CONTINUOUS HORMONE REPLACEMENT THERAPY: A CRITICAL REVIEW

  1995cited by this paper
• Measuring the impact of menopausal symptoms on quality of life.

  1993cited by this paper
• Guidelines for Counseling Postmenopausal Women about Preventive Hormone Therapy

  1992cited by this paper
• Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women

  1992cited by this paper
• Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆

  1991cited by this paper
• Decreased Mortality in Users of Estrogen Replacement Therapy

  1991cited by this paper

• Resveratrol and endothelial function: a literature review.

  2021cites this paper
• Progestins and the Risk of Breast Cancer.

  2021influential citation
• Perception of health, health behaviours and the use of prophylactic examinations in postmenopausal women

  2020cites this paper
• Cardiovascular Disease and the Menopause

  2020cites this paper
• Best practices in care for menopausal patients: 16 years after the Women's Health Initiative.

  2019cites this paper
• Prise de traitements hormonaux et risque de mélanome cutané dans les cohortes prospectives E3N et EPIC

  2019cites this paper
• Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study

  2019cites this paper
• Main Resveratrol Action Mechanisms in Postmenopausal Osteoporosis

  2019cites this paper
• Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition

  2019cites this paper
• Menopausal Hormone Therapy and Risk of Melanoma: A Nationwide Register-Based Study in Finland

  2019cites this paper
• Associations between Supplement Information Sources and Menopausal Women's Consumption of Herbal Supplements

  2018cites this paper
• Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study

  2017cites this paper
• OCORRÊNCIA DE SINTOMAS CLÍNICOS EM MULHERES CLIMATÉRICAS ASSISTIDAS EM UM SERVIÇO DE REFERÊNCIA EM SÃO LUÍS, MARANHÃO / SYMPTOMS OF OCCURRENCE IN CLINICAL WEATHER WOMEN IN SÃO LUIS, MARANHÃO, BRAZIL

  2017cites this paper
• Resveratrol Treatment Normalizes the Endothelial Function and Blood Pressure in Ovariectomized Rats

  2017cites this paper
• Aortic hemodynamics in postmenopausal women following cessation of hormone therapy

  2017cites this paper
• Biological Basis of Breast Cancer Prevention

  2016cites this paper
• Reproductive history and breast cancer prevention

  2016cites this paper
• A higher aneurysmal subarachnoid hemorrhage incidence in women prior to menopause: a retrospective analysis of 4,895 cases from eight hospitals in China.

  2016cites this paper
• Increased low back pain prevalence in females than in males after menopause age: evidences based on synthetic literature review.

  2016cites this paper
• Menopause as a potential cause for higher prevalence of low back pain in women than in age-matched men

  2016cites this paper
• Breast development and differentiation as the biological mechanism in cancer prevention

  2016cites this paper
• Le traitement hormonal de la ménopause (THM) chez les jeunes médecins généralistes de Gironde : connaissances, attitudes et pratiques

  2015cites this paper
• Cardiovascular Prevention at the Menopausal Transition: Role of Hormonal Therapies

  2015cites this paper
• EMAS position statement: The ten point guide to the integral management of menopausal health.

  2015cites this paper
• Effectiveness, tolerability and acceptance of a low-dosed estradiol/dienogest formulation (Lafamme 1 mg/2 mg) for the treatment of menopausal complaints: a non-interventional observational study over 6 cycles of 28 days

  2015cites this paper
• The Tissue-Selective Estrogen Complex: A Review of Current Evidence

  2015cites this paper
• Ospemifene for the treatment of dyspareunia in postmenopausal women.

  2014cites this paper
• [Climacteric syndrome in a Northeastern Brazilian city: a household survey].

  2014cites this paper
• Innovation in midlife health and beyond.

  2013cites this paper